| Therapy-related myelodysplastic syndromes in the genomics era |
|
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
|
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
|
Blood |
Aplastic Anemia |
| IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
|
Blood |
Aplastic Anemia |
| Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
|
Molecular Medicine |
Aplastic Anemia |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
